About Us


         Livzon Mabpharm Inc., a clinical stage biotechnology company, was co-founded in 2010 by two publically traded companies, the Livzon Pharmaceutical Group and Joincare, Inc.). Livzon Mabpharm Inc. is positioned to become a leader in the biopharmaceutical industry in China and a key contributor at the global level. We seek to improve patient health by bringing innovative and biosimilar type products to these markets.
        Currently, our development portfolio includes 11 molecules targeted towards indications in breast cancer, lymphoma, autoimmune disorders, and NSCLC etc.  One of our pipeline products has been granted “National Mega Innovative Program” status. Our facilities are3 housed in a newly built 170,000 ft2 R&D center, including clinical phase drug product production areas designed to meet the FDA/EMA and CFDA cGMP standards. Our capabilities reflect a highly trained and experienced staff, state-of-the-art R&D equipment from the US and EU, multiple single use bioreactors(50L to 2000L)and two independent stainless steel production lines (500 and 1500 L). With an average of 15 years of experience in global leading biotechnology companies in research and development, project management, international product registration, investigational and commercial drug production. Two members of our senior management team are recipients of the distinguished China “Thousand Talent Program” award.
         In addition, we continue to make substantial progress in developing international cooperative relationships, including partnerships with companies in Korea and the United States. We are seek to develop mutually beneficial relationships through joint ventures, external investments, as well as in- and out-licensing programs.